Stroke Alarm Efficacy Trial

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorRegion Skane

About this trial

The aim of this study is to test the efficacy of the CE-marked wearable system Stroke Alarm to identify the onset of a stroke with unilateral arm motor deficit within 3 hours of onset.

This is a multicenter, prospective observational single-arm trial with a registry-based propensity matched control population.

A total of 500 patients will be included in the trial. An interim analysis will determine if the stroke onset frequency is sufficient to determine the main outcome. Should the number of stroke events differ from what is expected at interim analysis, study enrollment will continue to increase cohort size.

Patients who meet the criteria for participation will, after signing consent, be included and receive the Stroke Alarm bracelets that are used for 3 months. Study data will be collected as baseline at inclusion, at follow-up 3 months after inclusion and by using national Swedish registry data after completion of the study.

Patients with elevated stroke risk according assessed by presence of specific criteria associated with elevated risk caused by:

1. recent TIA with an ABCD2 score of ≥6, large artery atherosclerosis or atrial fibrillation, OR 2. recent ischemic stroke with large artery atherosclerosis or atrial fibrillation, without persisting arm motor deficit, OR 3. atrial fibrillation with an CHA2DS2-Vasc score ≥ 4 without adequate anticoagulation OR 4. recent hemorrhagic stroke with atrial fibrillation, without persisting arm motor deficit The combined efficacy goal is at least 60% sensitivity for Stroke Alarm b of stroke with unilateral arm motor deficit within 3 hours of onset (with a 95% confidence interval above 30%) and a specificity of at least 80% using a clinical stroke diagnosis as gold standard.

A control population matched for calendar year, age (± 5 years), sex, healthcare region, baseline stroke severity according to the National Institutes of Health Stroke Scale (NIHSS, ± 5 points), unilateral arm motor deficit (NIHSS item 5a/5b 1-4), presence of neglect/inattention (NIHSS item 11 1-2), atrial fibrillation, cohabitation status and pre-stroke functional level twill be identified in the Swedish national stroke registry, Riksstroke, and used for comparison.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 50 years or older

Modified Rankin scale of 0-2.

Large artery atherosclerosis**.

Large artery atherosclerosis**. C. Atrial fibrillation/flutter (I48), AND

Disqualifiers

Previous inclusion in this study.

Arm motor deficit from any previous medical condition.

Unable to give informed consent to participate in the study.

Does not master any of the languages available within the Stroke Alarm smartphone app in speech and writing.

Trial design

Design model

Single group

Treatments tested in this trial

  • Stroke Alarm

    Device

    Patients who meet the criteria for participation will, after signing consent, be included and receive the Stroke Alarm bracelets that are used for 3 months. Study data will be collected as baseline at inclusion, at follow-up 3 months after inclusion and by using national Swedish registry data after completion of the study.

Treatment groups

500 Participants
are divided into 1 treatment group
Group A: Stroke Alarm useExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Alarm from device within 3 hours of onset of stroke with unilateral arm motor deficit.

The alarm is recorded systematically from the device backend. The ground truth is gathered based on the medical records for stroke events during the study period.

Time frame
From enrollment to the end of treatment at 3 months

Secondary outcomes

1

Time from onset of stroke with unilateral arm motor deficit until alarm by device.

2\. Time from onset of stroke with unilateral arm motor deficit until arrival to first hospital.

Time frame
From enrollment to the end of treatment at 3 months
2

Time from onset of stroke with unilateral arm motor deficit until arrival to first hospital.

The alarm is recorded systematically from the device backend. The ground truth is gathered based on the medical records for stroke events during the study period.

Time frame
From enrollment to the end of treatment at 3 months.
3

Number of alarms indicated by the device within 3 hours of onset, in patients with a subsequent clinical diagnosis of stroke.

The alarm is recorded systematically from the device backend. The ground truth is gathered based on the medical records for stroke events during the study period.

Time frame
From enrollment to the end of treatment at 3 months.
4

Number of alarms indicated by the device within 3 hours of onset, in patients with a subsequent clinical diagnosis of a stroke mimic.

The alarm is recorded systematically from the device backend. The ground truth is gathered based on the medical records for stroke events during the study period.

Time frame
From enrollment to the end of treatment at 3 months.

Other outcomes

1

Number of false alarms

False alarms generated by the device.

Time frame
From enrollment to the end of treatment at 3 months
2

Number of patients with missed strokes

Clinically diagnosed stroke events with unilateral arm paresis.

Time frame
From enrollment to the end of treatment at 3 months
3

Number of patients dying during the study period.

Death for any reason.

Time frame
From enrollment to the end of treatment at 3 months
4

Number of device-related events.

Adverse events related to the device.

Time frame
From enrollment to the end of treatment at 3 months

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Region Skane

Lead sponsor

Karolinska University Hospital

Collaborator

Stockholm South General Hospital

Collaborator

Sahlgrenska University Hospital

Collaborator

Skane University Hospital

Collaborator

Hässleholm Hospital

Collaborator

Uppsala University Hospital

Collaborator

Helsingborgs Hospital

Collaborator

University Hospital, Linkoeping

Collaborator